D. Boggs

发表

Cigarette smoking and mortality risk in people with schizophrenia.

D. Kelly, R. McMahon, H. Wehring, 2011, Schizophrenia bulletin.

The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans

D. Boggs, P. Skosnik, T. Surti, 2018, Journal of psychopharmacology.

The role of antihistaminic effects in the misuse of quetiapine: A case report and review of the literature

D. Boggs, B. Fischer, 2010, Neuroscience & Biobehavioral Reviews.

The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia

R. Conley, D. Kelly, R. McMahon, 2009, Clinical neuropharmacology.

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

D. Kelly, D. Boggs, R. Buchanan, 2012 .

Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

D. Boggs, J. Krystal, D. D’Souza, 2014, Current pharmaceutical design.

The 2009 schizophrenia patient outcomes research team (PORT) psychopharmacological treatment recommendations

D. Kelly, D. Boggs, R. Buchanan, 2011 .

A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.

R. Conley, D. Kelly, D. Boggs, 2009, The Journal of clinical psychiatry.

Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia

D. Kelly, D. Boggs, R. McMahon, 2013, Psychiatry Research.

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol

D. Boggs, M. Ranganathan, M. Taffe, 2018, Neuropsychopharmacology.

Diagnostic criteria for cannabis withdrawal syndrome.

D. Kelly, D. Boggs, S. Heishman, 2012, Drug and alcohol dependence.

Cannabis withdrawal in chronic cannabis users with schizophrenia.

D. Kelly, D. Boggs, D. Gorelick, 2013, Journal of psychiatric research.

Pilot study of Intravenous Nicotine Effects on Cognitive Performance in Schizophrenia

D. Boggs, D. D’Souza, M. Ranganathan, 2013, Schizophrenia Research.

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Julie Kreyenbuhl, Deanna L Kelly, D. Kelly, 2010, Schizophrenia bulletin.

Development of an instrument to measure knowledge about kidney function, kidney failure, and treatment options.

D. Boggs, J. Chambers, 1993, ANNA journal.

Quetiapine at high doses for the treatment of refractory schizophrenia

R. Conley, D. Kelly, D. Boggs, 2008, Schizophrenia Research.

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

D. Boggs, M. Niciu, T. Surti, 2018, Psychopharmacology.

Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion

D. Boggs, M. Ranganathan, Alyssa M. Peckham, 2016, The mental health clinician.

Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers.

D. Kelly, D. Boggs, S. Heishman, 2010, Drug and alcohol dependence.

Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice

R. Conley, D. Kelly, D. Boggs, 2008, Psychiatric Quarterly.

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

D. Boggs, M. Niciu, T. Surti, 2018, Psychopharmacology.

Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophrenia

D. Boggs, K. Cosgrove, T. Surti, 2017, Schizophrenia Research.

Reaching for wellness in schizophrenia.

R. Conley, D. Kelly, D. Boggs, 2007, The Psychiatric clinics of North America.

Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.

R. Conley, D. Kelly, D. Boggs, 2010, Comprehensive psychiatry.

A Survey of Prescribers' Attitudes, Knowledge, Comfort, and Fear of Consequences Related to an Opioid Overdose Education and Naloxone Distribution Program

D. Boggs, Alyssa M. Peckham, H. Steinberg, 2017, Journal of public health management and practice : JPHMP.

Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial

R. Conley, D. Kelly, D. Boggs, 2012, Schizophrenia Research.

Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study

R. Conley, D. Kelly, H. Wehring, 2011, Journal of clinical psychopharmacology.

Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

D. Kelly, D. Boggs, John M. Davis, 2008, Schizophrenia bulletin.

Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia

R. Conley, D. Kelly, D. Boggs, 2008, Schizophrenia Research.

Clinically Significant Interactions with Benzodiazepines

D. Boggs, J. Rey, J. Valdes, 2016 .

Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia

D. Kelly, D. Boggs, R. McMahon, 2013, Psychiatry Research.

Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics.

D. Boggs, D. D’Souza, M. Ranganathan, 2013, The primary care companion for CNS disorders.